The compound activated three receptor systems, improved metabolic outcomes in mice, and showed an early human pharmacokinetic profile compatible with weekly investigation.
Receptor assays, obese mice, and a first-in-human study
How the study was set up
The discovery program combined receptor assays, obese-mouse experiments, and an early single-exposure phase 1 study of LY3437943, now called retatrutide.
What the researchers measured
Receptor activity, food intake and energy expenditure, glucose and weight changes, tolerability, and drug persistence were examined.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
The different experiments support a development hypothesis but answer different questions. Mouse energy-expenditure mechanisms and early human observations do not establish long-term clinical outcomes.
What this does not establish
Discovery experiments and early human exposure do not establish long-term clinical benefit or retail-product equivalence.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.